TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose ...